Novartis has reported positive findings from the Phase III ASCLEPIOS I and II clinical trials of ofatumumab (OMB157), which met their primary endpoints in relapsing forms of multiple sclerosis (RMS) patients. Ofatumumab is an anti-CD20 monoclonal antibody (mAb) designed to cause B-cell lysis and depletion. It has been formulated for once-monthly, subcutaneous self-administration. The identical
Campaign will help Canadians to ‘SPOT’ fake news online by asking four critical questions News Media Canada today announced the launch of a new media literacy tool, SPOT Fake News Online, to help Canadians of all ages critically assess online news and information. “We know that so-called fake news, and the spread of disinformation online
Penn to Broaden Pathways for Development of New CAR T Cell Therapies Following a landmark, first-of-its-kind collaboration that spawned the global CAR T cell therapy industry, the University of Pennsylvania and Novartis have concluded their seven-year research and development alliance, which resulted in the world’s first approved gene therapy for cancer. They will continue to
A new gene therapy turns glial cells — abundant support cells in the brain — into neurons, repairing damage that results from stroke and significantly improving motor function in mice. A paper describing the new therapy, which uses the NeuroD1 gene, appears online in the journal Molecular Therapy. Once further developed, this NeuroD1-based gene therapy potentially
Regulators in the U.S. and Europe are investigating why traces of a possible carcinogen were found in certain heartburn drugs, including Zantac, more than a year after the same impurity was found in some blood pressure pills, a revelation that has raised questions about the safety of the pharmaceutical supply chain. At issue is NDMA,
If healthcare organizations want to succeed in an environment of digital transformation, they must bring about participatory health. That shift will require providers to be grounded in patient engagement and patient-centered care—by being “on-demand, connected and data-driven.” That’s the contention of a new report from the American Hospital Association’s Center for Health Innovation, and EY, which examines
Source Army.mil Doctors from 12 specialties taught 26 participants on required virtual health presentation skills at the eighth tri-service, inter-agency Virtual Health Patient Presenter course Sept. 9 – 13 at Landstuhl Regional Medical Center. The one-week course gave nurses, Army medics, Air Force medical technicians and Navy corpsmen hands-on instruction from specialty physicians and physician
Stem cell therapy, or stem cell transplant, is an emerging yet controversial treatment approach for multiple sclerosis (MS). While some data uphold it as one of the most efficacious MS treatments, to date there have been no controlled studies comparing it to conventional medicines and providing more robust evidence regarding its safety and clinical benefit. Under the topic
Source Targeted Oncology JAK inhibition continues to drive progress in myelofibrosis treatment as fedratinib (Inrebic) now joins ruxolitinib (Jakafi) in the treatment landscape for myelofibrosis. Since its FDA approval in August 2019, fedratinib has become both an additional treatment and a second-line option for patients who respond poorly to ruxolitinib. The approval of fedratinib was
Penn study finds immunotherapy reduces cardiac fibrosis and restores heart function in mice after cardiac injury CAR T-cell therapy, a rapidly emerging form of immunotherapy using patients’ own cells to treat certain types of cancers, may be a viable treatment option for another life-threatening condition: heart disease. In a first-of-its-kind study, published today in Nature, researchers
